Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Blueprint Medicines Corp (BPMC)

$97.75 0.49 (0.50%)

17:04 EDT BPMC Stock Quote Delayed 15 Minutes

Volume:

Previous Close $97.75

Market Cap 4.29B

PE Ratio -22.37

EPS -4.37

Volume (Avg. Vol.) 436,400

Day's Range 97.00 - 101.91

52-Week Range 44.58 - 101.91

Dividend & Yield N/A (N/A)

BPMC Stock Predictions, Articles, and Blueprint Medicines Corp News

From InvestorPlace
From the Web

Avis Budget Group Inc. (CAR) Leads 8 Notable Investor Filings

By Fintel May 4, 2017

13G and 13D filings are windows into recent activist investor activity. We look at Avis Budget Group Inc. (CAR) and 7 others

Notable Friday Option Activity: TUP, BPMC, AMBC

From Market News Video Jul 19, 2019

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Tupperware Brands Corp (TUP), where a total of 11,266 contracts have traded so far, representing approximately 1.1 million underlying shares. That amounts to about 191.4% of TUP's average daily trading volume over the past month of 588,685 shares..

Benzinga's Top Upgrades, Downgrades For July 19, 2019

From Benzinga Jul 19, 2019

Upgrades For American International Group Inc (NYSE: AIG), William Blair upgraded the previous rating of Market Perform to the current rating Outperform. American International...

Baird likes Blueprint Medicines in premarket analyst action

From Seeking Alpha Jul 19, 2019

Blueprint Medicines (NASDAQ:BPMC) initiated with Outperform rating and $120 (22% upside) price target at Baird.Millendo Therapeutics (NASDAQ:MLND) initiated with Outperform rating and $24 (125% upside

EMA accepts Blueprint's avapritinib application for GIST

From Seeking Alpha Jul 18, 2019

The European Medicines Agency (EMA) accepts for review Blueprint Medicines' (NASDAQ:BPMC) marketing application seeking approval to use lead candidate avapritinib (BLU-285) to treat adult pati

Benzinga's Top Upgrades, Downgrades For July 18, 2019

From Benzinga Jul 18, 2019

Top Upgrades Raymond James upgraded Skyworks Solutions Inc (NASDAQ: SWKS) from Market Perform to Outperform. Skyworks fell 0.8% to $79.50 in pre-market trading. Bank of America...

Wainwright sees 310% upside in Outlook Therapeutics in premarket analyst action

From Seeking Alpha Jul 18, 2019

Outlook Therapeutics (NASDAQ:OTLK) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up 11% premarket.Blueprint Medicines (NASDAQ:BPMC) initiated with Buy rating and $110 (14%

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!